19 results
To investigate feasibility, safety and toxicity as well as immune-response of an allogeneic tumor cell lysate (PheraLys) loaded onto autologous dendritic cells (MesoPher) in resected pancreatic cancer patients who received adjuvant standard of care…
This is a prospective phase II non-randomized single-center study in patients with LAPC. Patients are first treated with up to 8 cycles of FOLFIRINOX, followed by stereotactic radiotherapy for a total dose of 40 Gy in 5 fractions. Due to the known…
Primary Objective: The proposed project involves a phase II study to investigate the feasibility and safety of radiofrequency ablation in irresectable locally advanced pancreatic cancer. Secondary Objectives: Secondary objectives of the study are…
Primary Objective: - To investigate the efficacy of Namisol® after a single dose of Δ9-THC on the experienced pain intensity (measured by the VASpain in rest and on movement) in patients with chronic pancreatitis.Secondary Objectives:- To…
Primary objective: to investigate the safety of RFA in non-metastasized, irresectable locally advanced pancreatic cancer.Secondary objectives: to determine VAS pain score, length of hospital stay, survival, progression free survival and CA19-9…
Primary objective:- To investigate the analgesic efficacy of a stable dose treatment Namisol® in chronic pancreatitis patients suffering from abdominal pain. Analgesic efficacy is measured as mean difference in visual analogue scale (VAS) score (i.e…
In this pilot-study we investigate the safety, feasibility and efficacy of IRE in locally advanced pancreatic carcinoma. We hypothesize that IRE of the pancreas is a safe treatment that will cause few complications. Moreover, we expect the treatment…
To determine the efficacy and safety of MEDI4736 evaluated as a single agent or in combination with tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease has progressed on 5-FU-containing or gemcitabine-…
The first part of the study will focus on the feasibility of dendritic cell immunotherapy for pancereatic cancer patients.If this treatment is deemed feasible we will investigate immune-response, immune profile, clinical activity and safety and…
This study has been transitioned to CTIS with ID 2024-517267-23-00 check the CTIS register for the current data. The aim of this research is to investigate whether it is feasible and safe to pre-operatively treat patients who will undergo a distal…
The aim of this research is to investigate whether it is feasible and safe to treat operated pancreatic cancer patients who have completed standard of care treatment with dendritic cell immunotherapy using dendritic cells loaded with autologous…
To investigate the feasibility of using 18F-PSMA PET-CT as a tumor-specific molecular imaging in PC, thus allowing for improved detection, therapy selection, and therapy response assessment.
The main objective is to investigate the effect of oral tributyrin on plasma endotoxin in patients with acute pancreatitis.
This phase I/II study consists of 2 subsequent study parts. In the phase I part we will investigate the safety of combining IMM-101 administration with SBRT in 20 patients with locally advanced pancreatic cancer who have completed at least 4 cycles…
The objective of this study is to compare the efficacy of chemotherapy and IRE (experimental arm) to the efficacy of chemotherapy and radiation (control arm) in patients with locally advanced, non-resectable, non-metastasized, pancreatic cancer.
This study has been transitioned to CTIS with ID 2024-514598-23-00 check the CTIS register for the current data. This is an open-label, non-randomized, multicentre phase II study with an initial safety-run in. During the safety run-in phase, we will…
This study has been transitioned to CTIS with ID 2024-518627-29-00 check the CTIS register for the current data. PRIMARY OBJECTIVE• To compare the efficacy of Ampligen® versus control group / no treatment following FOLFIRINOX in subjects with…
The aim of this research is to investigate whether it is feasible and safe to treat operated pancreatic cancer patients who have completed standard of care treatment with dendritic cell immunotherapy using dendritic cells loaded with autologous…
Determine the efficacy and safety (using objective response rate) of tremelimumab in patients with advanced solid tumors (UBC, PDAC, TNBC).